- Timo grimmer is in the team - All endpoints of the clinical trial were reached I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

Anavex's A2-73 Blarcamesine's trial results on 2 previously completed adult phase-3 trials were highly successful.

$AVXL amazing avxl still in singke digits after a supposedly amazing “pivotal” trial readout 🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

Sava has potential and the phase 3 results will show the truth.

The introduction of Briumvi reduces the infusion time to one hour, shortening the patients’ time spent in a clinical setting and allowing them to enhance their quality of life.”

It bottomed in December at $0.55 and has since risen 300% on practically no news other than them having funding until 3Q23 and their primary pipeline item being an epilepsy drug currently in Phase 2.

This is a very defined space and the physicians involved with the trials are well respected and known within the MS community cheers everyone

up 290% After Positive Resmetirom Liver Treatment Phase3 Trial data.

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.

The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.

$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.

$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.

$SAVA , VERA announced positive phase 2b results meeting primary end point.

My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients